Is E-cadherin a useful surrogate marker to predict chemosensitivity of chemotherapy for triple-negative breast cancer?

被引：1
|
作者：
Kashiwagi, S. [1 ]
Yashiro, M. [1 ]
Takashima, T. [1 ]
Aomatsu, N. [1 ]
Kawajiri, H. [1 ]
Onoda, N. [1 ]
Nakata, B. [1 ]
Ishikawa, T. [1 ]
Hirakawa, K. [1 ]
机构：
[1] Osaka City Univ, Dept Surg Oncol, Grad Sch Med, Osaka 558, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.1077
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1077
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Androgen receptor (AR), E-cadherin, and Ki-67 as prognostic markers in triple-negative breast cancer (TNBC)
    Ricciardi, Giuseppina R. R.
    Adamo, Barbara
    Ferraro, Giuseppa
    Franchina, Tindara
    Zanghi, Mariangela
    Buda, Carmelo
    Trimarchi, Giuseppe
    Cardia, Roberta
    Tuccari, Giovanni
    Adamo, Vincenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [22] Prognostic markers in triple-negative breast cancer (TNBC): The role of androgen receptor, e-cadherin, and Ki67.
    Ricciardi, Giuseppina Rosaria Rita
    Adamo, Barbara
    Barresi, Valeria
    Ieni, Antonio
    Franchina, Tindara
    Caruso, Michele
    Zacchia, Alessandra
    Fazzari, Carmine
    Tuccari, Giovanni
    Adamo, Vincenzo
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [23] E-Cadherin in Colorectal Cancer: Relation to Chemosensitivity
    Druzhkova, Irina
    Ignatova, Nadezhda
    Prodanets, Natalia
    Kiselev, Nikolay
    Zhukov, Iliya
    Shirmanova, Marina
    Zagainov, Vladimir
    Zagaynova, Elena
    CLINICAL COLORECTAL CANCER, 2019, 18 (01) : E74 - E86
  • [24] ZEB1 Collaborates with ELK3 to Repress E-Cadherin Expression in Triple-Negative Breast Cancer Cells
    Cho, Hyeon-Ju
    Oh, Nuri
    Park, Ji-Hoon
    Kim, Kwang-Soo
    Kim, Hyung-Keun
    Lee, Eunbyeol
    Hwang, Sohyun
    Kim, Seong-Jin
    Park, Kyung-Soon
    MOLECULAR CANCER RESEARCH, 2019, 17 (11) : 2257 - 2266
  • [25] E-cadherin inactivation by Trop-2 drives EMT-less metastatic relapse in triple-negative breast cancer
    Alberti, S.
    Guerra, E.
    Lattanzio, R.
    Ceci, M.
    Boujnah, K.
    Relli, V.
    Garbo, V.
    Moschella, A.
    Altomare, D.
    Depalo, R.
    Trerotola, M.
    ANNALS OF ONCOLOGY, 2021, 32 : S66 - S66
  • [26] Expression of p53, Ki-67, E-Cadherin, N-Cadherin and TOP2A in Triple-negative Breast Cancer
    Nakagawa, Misako
    Bando, Yoshimi
    Nagao, Taeko
    Morimoto, Masami
    Takai, Chikako
    Ohnishi, Takamasa
    Honda, Junko
    Moriya, Takuya
    Izumi, Keisuke
    Takahashi, Masako
    Sasa, Mitsunori
    Tangoku, Akira
    ANTICANCER RESEARCH, 2011, 31 (06) : 2389 - 2393
  • [27] RespondR: A genomic score to predict the responsiveness of triple-negative breast cancer patients to chemotherapy
    Buechler, Steven
    Gokmen-Polar, Yesim
    Badve, Sunil S.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [28] Trop-2 inactivation of E-cadherin drives triple negative breast cancer relapse
    Alberti, Saverio
    Trerotola, Marco
    Relli, Valeria
    Lattanzio, Rossano
    Ceci, Martina
    Boujnah, Khouloud
    Garbo, Valeria
    Moschella, Antonino
    Querzoli, Patrizia
    Pedriali, Massimo
    Antolini, Laura
    Guerra, Emanuela
    CANCER RESEARCH, 2021, 81 (04)
  • [29] Pembrolizumab plus Chemotherapy for triple-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1114 - 1114
  • [30] Chemotherapy for Triple-Negative Breast Cancer: Is More Better?
    Mayer, Erica L.
    Burstein, Harold J.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (28) : 3369 - +
12345